Semaglutide 2.4 mg Weekly for Obesity: STEP-1 Phase III Trial
Study Overview
| Primary Reference | Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384(11):989–1002. PMID: 33567185 |
| Study Design | Phase III, randomized (2:1 active:placebo), double-blind, placebo-controlled, multicenter |
| N (enrolled) | 1,961 adults (BMI ≥30, or ≥27 with ≥1 weight-related comorbidity) |
| Intervention | Semaglutide 2.4 mg SC once weekly vs. placebo; both groups with lifestyle intervention counseling |
| Duration | 68 weeks (16-week dose escalation, then 52 weeks at target dose) |
| Primary Endpoints | % change in body weight at week 68; proportion of participants achieving ≥5% weight loss |
| Key Finding | Mean -14.9% body weight reduction (vs. -2.4% placebo); 69.1% of participants achieved ≥10% weight loss; landmark trial establishing GLP-1 agonism as a primary pharmacological obesity treatment |
Background
Semaglutide (Ozempic/Wegovy; Novo Nordisk) is a synthetic GLP-1 receptor agonist with 94% structural homology to native GLP-1(7-36)amide. The modifications relative to native GLP-1 include C18 fatty acid attachment at Lys26 (enabling albumin binding and extending the half-life to ~7 days), an Aib substitution at position 8 (resistance to DPP-IV), and two additional amino acid substitutions. The weekly dosing interval made semaglutide the first once-weekly injectable GLP-1 agonist and drove the clinical development for both T2DM glycemic control (Ozempic, 0.5–1 mg) and obesity treatment (Wegovy, 2.4 mg).
The STEP program (Semaglutide Treatment Effect in People with obesity) was a four-trial Phase III program designed to establish the efficacy and safety of semaglutide 2.4 mg for chronic weight management. STEP-1 was the pivotal trial in subjects without T2DM and remains the most widely cited semaglutide weight loss study. It was published in the New England Journal of Medicine in February 2021 and led to FDA approval of Wegovy (semaglutide 2.4 mg) in June 2021.
At the time of its publication, the 14.9% mean weight loss achieved by semaglutide was the highest reported in any large-scale pharmacological obesity trial, establishing the GLP-1 agonist class as the dominant pharmacological approach to obesity treatment — a paradigm subsequently extended by tirzepatide and retatrutide.
Methods
Population and eligibility
Adults (≥18 years) with BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). Exclusion criteria included T2DM (HbA1c ≥6.5%), prior bariatric surgery, prior use of GLP-1 agonists, and severe renal or hepatic impairment. Mean baseline characteristics: weight 105.4 kg; BMI 37.9 kg/m²; 74% female; 75% white.
Dose escalation
Semaglutide was initiated at 0.25 mg weekly and escalated every 4 weeks: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg. The 16-week escalation was designed to minimize GI adverse events during dose titration. Dose maintenance could be extended at the prescribing physician's discretion if tolerability was suboptimal.
Lifestyle intervention
Both active and placebo groups received standardized dietary counseling (500 kcal/day deficit diet) and physical activity guidance (≥150 min/week moderate activity) throughout the trial. This is a critical design feature — the placebo group lost a meaningful 2.4% of body weight on lifestyle intervention alone, and the semaglutide treatment effect must be interpreted relative to this active comparator, not against an untreated control.
Statistical analysis
The primary estimands were defined under the "treatment policy" assumption (all randomized subjects regardless of drug discontinuation) and the "hypothetical" assumption (only subjects remaining on drug). This dual estimand approach was pre-specified to provide both intention-to-treat and per-protocol interpretations of efficacy. All efficacy analyses were MMRM-based with ANCOVA adjustment for baseline weight and key stratification factors.
Results
Primary endpoints — weight change at week 68
| Endpoint | Semaglutide 2.4 mg | Placebo | Difference (95% CI) | p-value |
|---|---|---|---|---|
| Mean % body weight change | -14.9% | -2.4% | -12.4 pp (−13.4 to −11.5) | p < 0.001 |
| Mean absolute weight loss (kg) | -15.3 kg | -2.6 kg | -12.7 kg | p < 0.001 |
| Proportion achieving ≥5% WL | 86.4% | 31.5% | OR 14.7 (11.1–19.5) | p < 0.001 |
Responder analysis — weight loss thresholds
| Weight Loss Threshold | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| ≥5% body weight loss | 86.4% | 31.5% |
| ≥10% body weight loss | 69.1% | 12.0% |
| ≥15% body weight loss | 50.5% | 4.9% |
| ≥20% body weight loss | 32.0% | 1.7% |
Cardiometabolic secondary endpoints
| Secondary Endpoint | Semaglutide (change) | Placebo (change) | p-value |
|---|---|---|---|
| Waist circumference | -13.5 cm | -4.1 cm | p < 0.001 |
| Systolic blood pressure | -6.2 mmHg | -1.4 mmHg | p < 0.001 |
| HbA1c | -0.23% | -0.06% | p < 0.001 |
| Fasting triglycerides | -20.3% | -8.9% | p < 0.001 |
| HOMA-IR (insulin resistance) | -40.4% | -15.4% | p < 0.001 |
| Physical functioning score (IWQOL-Lite) | +13.7 points | +9.0 points | p < 0.001 |
Safety and tolerability
Nausea was the most common adverse event (44.2% semaglutide vs. 16.0% placebo), followed by diarrhea (29.7% vs. 15.9%) and vomiting (24.5% vs. 6.8%). The majority were mild-to-moderate and concentrated during the dose escalation phase. Serious adverse events occurred in 9.8% (semaglutide) vs. 6.4% (placebo). Discontinuation due to AEs: 7.0% vs. 3.1%. No cases of pancreatitis or thyroid cancer were reported in this study. Three participants developed cholelithiasis in the semaglutide group during the trial — subsequent large-scale data has confirmed increased gallstone risk with GLP-1 agonists.
Proposed Mechanism
Central appetite suppression
Semaglutide binds GLP-1R in hypothalamic nuclei (arcuate, paraventricular, and dorsomedial hypothalamus) and brainstem (nucleus tractus solitarius, area postrema). In the arcuate nucleus, GLP-1R activation stimulates pro-opiomelanocortin (POMC)/CART neurons (anorexigenic) and inhibits NPY/AgRP neurons (orexigenic), shifting the hypothalamic set point toward reduced appetite. The area postrema — outside the blood-brain barrier — senses peripheral GLP-1 and projects satiety signals to the nucleus tractus solitarius, providing a direct chemosensory pathway for peripheral semaglutide to reach CNS appetite circuits.
Gastric motility slowing
Peripheral GLP-1R activation in the myenteric plexus slows gastric emptying, prolonging distension-mediated satiety signals after meals. This "ileal brake" effect contributes to reduced caloric intake per meal. Notably, this gastric motility effect also drives the nausea and vomiting adverse events at initiation — the GI side effects and the central appetite suppression are mechanistically related but can be partially titrated independently through slow dose escalation.
Adipose tissue and liver effects
GLP-1R is expressed in adipocytes, where activation promotes lipolysis and inhibits lipid storage. In the liver, GLP-1R activation reduces hepatic gluconeogenesis and lipid accumulation — the latter relevant to the emerging interest in GLP-1 agonists for non-alcoholic steatohepatitis (NASH). These peripheral effects contribute to the favorable lipid profile and HOMA-IR improvements observed in STEP-1 independent of weight loss per se, though their relative contribution is difficult to disentangle from weight-loss-mediated improvements.
Limitations
- Weight regain on discontinuation: Subsequent studies (including STEP-4 extension data) confirmed that the weight reduction achieved with semaglutide is substantially reversed within 12 months of discontinuation, with participants regaining approximately 2/3 of lost weight. This establishes semaglutide as a chronic therapy, not a curative intervention
- Predominantly female, white population: 74% female and 75% white composition limits generalizability across sex and ethnicity. Subsequent STEP trials and real-world data show similar directional results but different absolute effect sizes in diverse populations
- 65% of lost weight regained post-trial: The lifestyle-only group's weight trajectory at trial end (downward trend) suggests the optimal trial duration for STEP-1's design may have been longer to capture full steady-state weight loss
- No cardiovascular outcomes data at time of publication: The SELECT trial (cardiovascular outcomes) was completed subsequently and published in 2023, showing 20% reduction in MACE events — but STEP-1 itself did not assess CV outcomes
- Lean mass loss: Body composition sub-studies indicate approximately 39% of total weight loss in the semaglutide group was lean mass — a concern in an aging population. This has driven interest in combination with resistance exercise protocols and emerging data on muscle-preserving combination approaches
Research Significance
The STEP-1 trial fundamentally changed how obesity is treated pharmacologically. Its publication in February 2021 triggered the largest pharmaceutical demand disruption in endocrinology history — within 18 months of FDA approval, demand for Wegovy and its related compound Ozempic exceeded manufacturing capacity globally. The trial established three lasting contributions to obesity science.
First, it demonstrated that GLP-1R agonism at therapeutic doses produces weight loss that is qualitatively different from prior pharmacotherapy — not 3–5% "modest" weight loss, but 15% mean reduction with >50% of patients losing ≥15%. This magnitude shifts the pharmacological efficacy ceiling to a range previously associated only with bariatric surgery.
Second, the cardiometabolic secondary endpoints — particularly the improvements in blood pressure, HbA1c, and lipids at magnitudes disproportionate to weight loss alone — provided mechanistic evidence that GLP-1R agonism has pleiotropic metabolic benefits independent of caloric restriction, supporting the subsequent SELECT cardiovascular outcomes trial.
Third, STEP-1 established the methodological framework (dual-estimand approach, 68-week minimum duration, MMRM-based primary analysis) that became the de facto standard for all subsequent obesity drug trials, including tirzepatide's SURMOUNT program and retatrutide's Phase II/III designs.
Full Citations
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. PMID: 33567185
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–1844. PMID: 27633186
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221–2232. PMID: 37952131
- Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414–1425. PMID: 33755728
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756. PMID: 29617641